YB3 Stock Overview
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Shin Nippon Biomedical Laboratories, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.40 |
| 52 Week High | JP¥17.10 |
| 52 Week Low | JP¥8.40 |
| Beta | 0.018 |
| 1 Month Change | -9.19% |
| 3 Month Change | -17.65% |
| 1 Year Change | -48.47% |
| 3 Year Change | 55.56% |
| 5 Year Change | 41.06% |
| Change since IPO | -33.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| YB3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -9.9% | -2.0% |
| 1Y | -48.5% | -14.9% | -0.3% |
Return vs Industry: YB3 underperformed the German Life Sciences industry which returned -14.9% over the past year.
Return vs Market: YB3 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| YB3 volatility | |
|---|---|
| YB3 Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YB3's share price has been volatile over the past 3 months.
Volatility Over Time: YB3's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,344 | Ryoichi Nagata | www.snbl.co.jp |
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services.
Shin Nippon Biomedical Laboratories, Ltd. Fundamentals Summary
| YB3 fundamental statistics | |
|---|---|
| Market cap | €361.72m |
| Earnings (TTM) | €33.37m |
| Revenue (TTM) | €161.91m |
10.8x
P/E Ratio2.2x
P/S RatioIs YB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YB3 income statement (TTM) | |
|---|---|
| Revenue | JP¥26.70b |
| Cost of Revenue | JP¥12.77b |
| Gross Profit | JP¥13.94b |
| Other Expenses | JP¥8.43b |
| Earnings | JP¥5.50b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 132.18 |
| Gross Margin | 52.19% |
| Net Profit Margin | 20.61% |
| Debt/Equity Ratio | 87.4% |
How did YB3 perform over the long term?
See historical performance and comparison